Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented as Platform Presentation

Aerosurf Utilizing Chrysalis Aerosol-Generator Technology Demonstrates Optimal Functional Activity

WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that results from its previously completed Phase 2 clinical trial of Surfaxin(r) (lucinactant intratracheal suspension) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) were selected and presented as a platform presentation at the Pediatric Academic Societies' (PAS) Annual Meeting in Toronto, Canada. Also presented at PAS were data regarding Discovery's novel aerosolized KL-4 surfactant, Aerosurf(tm) (lucinactant for inhalation). The Pediatric Academic Societies' annual meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric critical care research. These data were presented for the first time to the medical community.

Phase 2 Clinical Trial of Surfaxin(r) for the Prevention and Treatment of BPD

Carl Bose, MD, Director of Neonatology and Professor of Pediatrics at University of North Carolina and Chairman of the Discovery BPD Clinical Study Steering Committee, presented an overview of key trial data. These data suggest that Surfaxin, when administered beyond the standard acute Respiratory Distress Syndrome (RDS) treatment period, may represent a novel therapeutic option for infants at risk for developing BPD. BPD is a chronic, debilitating lung disease affecting premature infants who survive treatment for RDS. Presently, there are no approved pharmaceutical therapies for BPD.

Surfaxin was shown to be generally safe and well-tolerated. Top-line results demonstrated that infants treated with up to five incremental standard doses of Surfaxin experienced:

* a lower incidence of death or BPD,

* a higher survival rate thr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:6/30/2015)... , June 30, 2015 First Choice ... to the Astanza Duality and is the only clinic ... offering professional tattoo removal treatments. The practice has recently ... Removal brand to showcase their focus in the ... residents better results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... Company focused on the development of oral drug delivery ... screened in the Company,s Phase IIb trial of its ... be performed under the active Investigational New Drug (IND) ... Administration (FDA). The Phase IIb study for ...
(Date:6/30/2015)... 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering  of 40,229,886 units. Each unit consists of one ... warrant to purchase one share of common stock, and ... share of common stock, at a purchase price of ...
Breaking Medicine Technology:First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... Sibutramine -- ABBOTT PARK, Ill., Sept. 15 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
Cached Medicine Technology:Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 2Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 3Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 4Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 5Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 6Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 7Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 8Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine 9Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4
(Date:7/1/2015)... ... ... The Thule Atmos X4 offers protection with minimal bulk. At the Thule ... rigorous standards. Due to its Bi-ComponentArmor and ShockStop corners, it passed Thule’s 2 meter ... , The Thule Atmos X4 has also been designed with function in mind. ...
(Date:7/1/2015)... ... July 01, 2015 , ... AvePoint, ... the opening of a new operational office in Zurich, Switzerland. The new facility ... all lines of business for organizations throughout the Swiss market. , “AvePoint ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... (RFID) safety and security solutions, has partnered with WIU Crossroads School in safeguarding ... Solution. The unique AEDY (Alternative Education for Disruptive Youth) environment of Crossroads School ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... cannabis space, created a web-based resource where legal cannabis startups can ... together visionary entrepreneurs and medical marijuana advocates looking to strategically enter and capitalize ...
(Date:7/1/2015)... ... July 01, 2015 , ... This ... Patient Self-Management (PSM) Solutions at the Society for Human Resource Management (SHRM) Annual ... for over 10 years, can reduce overall cost of care by approximately $1,000 ...
Breaking Medicine News(10 mins):Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3Health News:WIU Crossroads School Chooses Help Alert Mobile Staff Duress Pendants from RF Technologies to Safeguard Staff and Students, De-escalate Altercations 2Health News:WIU Crossroads School Chooses Help Alert Mobile Staff Duress Pendants from RF Technologies to Safeguard Staff and Students, De-escalate Altercations 3Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 3Health News:APhA Foundation to Showcase Newly Introduced Patient Self-Management Solutions at the Society for Human Resource Management (SHRM) Annual Conference and Exposition 2
... FRIDAY, Aug. 27 (HealthDay News) -- While attention-deficit hyperactivity disorder ... there is a cluster of kids and adults who successfully ... privileges in school. "People who want to fake ADHD ... on a number of standard clinical instruments that are used ...
... of Texas at Austin,s new Health Information Technology program ... Professional University Resources and Education for Health Information Technology ... the U.S. Department of Health and Human Services Office ... The program graduated its first class of 54 ...
... Standard/Elsevier, developer of drug databases and medication management solutions, ... and Federal module, the first and only database to ... The Alchemy State and Federal module will ... Programs (PDMPs) and federal regulations, while also controlling increasingly ...
... , PITTSBURGH, Aug. 27 Mothers who did not ... diabetes later in life than moms who breastfed , report ... September issue of the American Journal of Medicine. ... type 2 diabetes over the last century," said Eleanor Bimla ...
... considered a singular event by the insurance industry and ... an ongoing process that impacts multiple organ systems and ... can reduce life expectancy, according to research from the ... such, traumatic brain injury should be defined and managed ...
... Alan Mozes HealthDay Reporter , THURSDAY, Aug. 26 ... almost twice as likely as their religious counterparts to make ... more quickly, a new British study reveals. "The religious ... dying people," concludes study author Clive Seale, a professor of ...
Cached Medicine News:Health News:Some Fake ADHD to Get Meds, Special Treatment 2Health News:Some Fake ADHD to Get Meds, Special Treatment 3Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 2Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 3Health News:Gold Standard/Elsevier first to launch state, federal controlled substance drug schedules 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 3Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 4Health News:Doctors' Religious Beliefs Can Color Their Care of Terminally Ill 2Health News:Doctors' Religious Beliefs Can Color Their Care of Terminally Ill 3Health News:Doctors' Religious Beliefs Can Color Their Care of Terminally Ill 4
For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
... the first manufacturer to offer through-the-lens ... wearer. These next generation loupes feature ... ultra-lightweight design, and are multi-coated lens ... With SheerVision's proprietary SureFit system - ...
Medicine Products: